Clinical use of streptolysin-O to facilitate antisense oligodeoxyribonucleotide delivery for purging autografts in chronic myeloid leukaemia

被引:17
作者
Clark, RE
Grzybowski, J
Broughton, CM
Pender, NT
Spiller, DG
Brammer, CG
Giles, RV
Tidd, DM
机构
[1] Royal Liverpool Univ Hosp, Dept Haematol, Liverpool L7 8XP, Merseyside, England
[2] Univ Liverpool, Sch Biol Sci, Liverpool L69 3BX, Merseyside, England
关键词
chronic myeloid leukaemia; blood and marrow transplantation; streptolysin-O; antisense oligodeoxyribonucleotides; BCR-ABL;
D O I
10.1038/sj.bmt.1701801
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Antisense oligodeoxyribonucleotides (ODN) targeted against the breakpoint in BCR-ABL mRNA will specifically decrease BCR-ABL mRNA, provided cells are first permeabilised with streptolysin-O (SL-O), We used 18-mer chimeric methylphosphonodiester: phosphodiester linked (4-9-4) ODN complementary to 9 bases either side of the BCR-ABL junction to purge harvests ex vivo in three CML patients who remained completely Ph positive after multiple chemotherapy courses. After CD34(+) cell selection and SL-O permeabilisation, harvests were purged,vith 20 mu M ODN, After purging, all individual CFU-GM colonies grown from the two b3a2 breakpoint cases remained positive for BCR-ABL mRNA, In contrast, all 24 colonies grown from the b2a2 breakpoint case were BCR-ABL mRNA negative. Patients were conditioned with busulphan 16 mg/kg. The initial post-transplant course was uneventful, although the time to return to 0.5 x 10(9)/l neutrophils was slow at 25-51 days. Both chronic phase patients remain in haematological remission at +724 and +610 days, although each has cytogenetic evidence of relapse. The b2a2 accelerated phase patient died of myeloid blast transformation at day +91, The present SL-O-facilitated ODN purging strategy appears to be without significant toxicity, and offers considerable improvements in ODN delivery to the cytosol.
引用
收藏
页码:1303 / 1308
页数:6
相关论文
共 24 条
[21]   The influence of target protein half-life on the effectiveness of antisense oligonucleotide analog-mediated biologic responses [J].
Spiller, DG ;
Giles, RV ;
Broughton, CM ;
Grzybowski, J ;
Ruddell, CJ ;
Tidd, DM ;
Clark, RE .
ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, 1998, 8 (04) :281-293
[22]   Improving the intracellular delivery and molecular efficacy of antisense oligonucleotides in chronic myeloid leukemia cells: A comparison of streptolysin-O permeabilization, electroporation, and lipophilic conjugation [J].
Spiller, DG ;
Giles, RV ;
Grzybowski, J ;
Tidd, DM ;
Clark, RE .
BLOOD, 1998, 91 (12) :4738-4746
[23]   NUCLEAR DELIVERY OF ANTISENSE OLIGODEOXYNUCLEOTIDES THROUGH REVERSIBLE PERMEABILIZATION OF HUMAN LEUKEMIA-CELLS WITH STREPTOLYSIN-O [J].
SPILLER, DG ;
TIDD, DM .
ANTISENSE RESEARCH AND DEVELOPMENT, 1995, 5 (01) :13-21
[24]   BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients [J].
Verfaillie, CM ;
Bhatia, R ;
Miller, W ;
Mortari, F ;
Roy, V ;
Burger, S ;
McCullough, J ;
Stieglbauer, K ;
Dewald, G ;
Heimfeld, S ;
Miller, JS ;
McGlave, PB .
BLOOD, 1996, 87 (11) :4770-4779